SCM
LBRX

Sterling Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Sterling Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.07K Sell
368
-224
-38% -$5.17K ﹤0.01% 2422
2025
Q4 		$13.2K Buy
+592
New +$10.3K ﹤0.01% 2469

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Sterling Capital Management's LBRX Position: Q1 2026 in Review

Sterling Capital Management reduced its LB Pharmaceuticals (LBRX) stake by 38% in Q1 2026, selling an estimated $5.17K and leaving 368 shares worth $9.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Sterling Capital Management first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $13.2K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Sterling Capital Management held 368 shares of LB Pharmaceuticals worth $9.07K as of Q1 2026.
  • Sterling Capital Management sold 224 LB Pharmaceuticals shares in Q1 2026, an estimated $5.17K.
  • LB Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2422 holding.
  • Sterling Capital Management first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sterling Capital Management's LB Pharmaceuticals position peaked at $13.2K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.